Chemotherapy of breast cancer: Are the taxanes going to change the natural history of breast cancer?

Expert Opinion on Pharmacotherapy

Volumn 1, Issue 2, 2000, Pages 187-206

  Nabholtz, Jean Marc ^a   Tonkin, Katia ^a   Smylie, Mike ^a   Au, Heather Jane ^a   Lindsay, Mary Ann ^a   Mackey, John ^a  

^a CROSS CANCER INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BRIDGED COMPOUND; TAXANE; TAXOID;

ANIMAL; BREAST TUMOR; FEMALE; HUMAN; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; FEMALE; HUMANS; TAXOIDS;

EID: 0033760022     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.1.2.187     Document Type: Article

References (129)

1. LANDIS SH, MURRAY T, I5OLDEN S, WINGO PA: Cancer statistics, 1999. CA Cancer J. Clin. (1999) 49:8-31.
2. HENDERSON 1C: Chemotherapy for metastatic disease. In: Breast Diseuses (2nd edition). Harris JR, Hellman S, Henderson 1C et at. (Eds.), Lippincott, Philadelphia, PA. USA (1990:604-665.
3. CROWN J: Evolution in the treatment of advanced breast cancer. Semin. Oncol. (1998) 25(Suppl. 12):12-17.
4. HULL JM, TORiMEY DC, LI SU cl a!.: A randomized comparative trial of Adriamycin versus methotrcxatc in combination chemotherapy. Cancer (1978) 41:1649-1657.
5. CUMMINGS FJ, GELMAN R, HORION J étal.: Comparison of CAP versus CMFP in metastatic breast cancer: analysis of prognostic factors. / Clin. Oncol. (1985) 3:932-940.
6. AISNER J, WEINBERG V, PERLOFF M et al.: Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER for metastatic carcinoma of the breast: a CALGB study./ Clin. Oncol. (1987) 5:1523-1533.
7. FALKSON G, TORMEY DC, CAREY P et at.-. Long-term survival of patients treated with combination chemotherapy for metastatic breast cancer. Enr. J. OîHcer(1991) 27:973-977.
8. FOSSATI R, CONFALOiN'IERKI C, TORRI V et al.-. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J. Clin. Oncol. (1998) 16(10):3439-3460.
9. GKEENBERG PAC. HORTOÜAGYI GN, SMITH TL el ill.: Long-term follow-up of patients with complete remission following combination chemotherapy for mctastatic breast cancer. .J. Clin. Oncol. (1996) 14(8):2197-2205.
10. JOENSUU H. HOLLI K. HEIKKINEN M et al:. Combination chemotherapy versus single-agent therapy as firstand second-line treatment in metastatic breast cancer: a prospective randomized trial. / din. Oncol. (1998) 16U2):3720-3730.
11. LEVINE MN, BRAMVi'ELL VH. PRITCHARD KI et eil.: Randomized trial of intensive cyclophosphamidc, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamidc, mcthotrcxatc, and fluorouracil in prcmcnopausal women with node-positive breast cancer. J. Clin. Oncol. (1998) l6(8):2651-2658.
12. COOMI3ES RC, BLISS JM, \VILS J el til.: Adjuvant cyclophosphamidc, mcthotrcxatc, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in prcmcnopausal women with axillary node-positive operable breast cancen results of a randomized trial. J. din. Oncul. (1996) l4U):35-45.
13. BONADONNA G, ZAMBETTI M, VALAGUSSA [': Doxorubicin followed by cyclophosphamidc, mcthotrcxatc, and fluorouracil for breast cancer (letter). JAMA (1995) 274(10):796-797.
14. MISSET J-L. DI I'ALMA M, DELGADO M et al.: Adjuvant treatment of node-positive breast cancer with cyclophosphamidc, doxorubicin, fluorouracil, and vincristinc versus cyclophosphamide, methotrexatc, and fluorouracil: final report after a 16-year median follow-up duration./ din. Oncol. (1996) 14:1136-1145.
15. CARPENTER JT, VELEZ-GARCIA E, ARON BS et al.: Five-year results of a randomized comparison of cyclophosphamidc, doxorubicin (adriamycin) and fluorouracil (CAP) vs. cyclophosphamide, methotrexatc and fluorouracil (CMF) for node positive breast cancer. Pmc. Am. Soc. Clin. Oncol. (199-i) 13:66. Abstract 68.
16. EARLY BREAST CANCER TRIALISTS' COLLABORATIVE GROUP: Polychemothcrapy for early breast cancer: an overview of the randomised trials. Lancet (1998) 352:930-942.
17. WAN1 MC, TAYLOR ML, WALL ME, COGGON P, MCPHAIL AT: Plant antitumour agents VI. The isolation and structure of Taxol, a novel antilcukcmic and antitumour agent from Taxus brevifolia.J. Am. Cl.wm. Soc. (1971) 93:2325-2327.
18. ROWINSKY EK, DONEHOWER RC: Drug therapy: paclitaxel (Taxol). N.EngI.J.Med.(.1995) 332:1004-1014.
19. LAVELLE F, GUERITTE-VOEGELEIN F, GUENARD D: Le Taxotcrc: des aiguilles d'if a la clinique. Bull. Cancer (1993) 80:326-338.
20. BISSERY MC, NOHYNEK G, SANDERINK GJ et al.: Docetaxel (Taxotere): a review of preclinical and clinical experience. Part 1: prcclinical experience. AntiCancer Drugs (1995) 6:339-368.
21. LEGHA SS. TENNEY DM. KRAKOFF IR: Phase I study of Taxol using a 5 clay intermittent schedule. J. Gin. Oncol. (1986)4:762-766.
22. GRE.M JL. TUTSCH KD, SIMON K.I et ai: Phase I study of Taxol administered as a short i.V. infusion daily for 5 days. CimcerTmit. Rep. (1986) 71:1179-1184.
23. DONEHOWEK RC, RO\VINSKY EK, GROCHOW LB ct at.: Phase I trial of Taxol in patients with advanced cancer. Cancer Treat. Rep. (1987) 71:1171-1177.
24. WIERNIK PH. SCHWAKTZ EL, STRAUMAN JJ et cil.: Phase I clinical and pharmacokinetic study of Taxol. Cancer Kc-s. (1987) 47:2486-2493.
25. SCHILLER JH, STOKER B. TUTSCH K et cil.: Phase I trial of 3-hour infusion of paclitaxcl with or without granulocytc colony-stimulating factor in patients witli advanced cancer./ Gin. Oncol. (1990 12: 241-248.
26. KR1S MG. O'CONNELLJP, GKALLA RJ elal.: Phase I trial of Taxol given as a 3-hour infusion every 21 days. Cancer Treat. Ke{>. (1986) 70:605-607.
27. BROWN T, HALVIN K, WEISS G et ni.: A Phase I trial of Taxol given by a 6-hour intravenous infusion. J. din. Oncol. (1991) 9:1261-1267.
28. WIERNIK PH, SCHWARTZ EL, EINZIG A et al.-. Phase I trial of Taxol given as a 24-hour infusion every 21 days: responses observed in mctastatic melanoma. J. Gin. Oncol. (1987)5:1232-1239.
29. OHMURA T, ZIMET AS, COFFEY VA et al.: Phase I study of Taxol in a 24-hour infusion schedule. Pmc. Am. Soc. Gin. Oncol. (1985) 26:167.
30. HURVCTTZ CA. RELLING MV, WHITMAN SD et ai: Phase I trial of paclitaxcl in children with refractory solid tumors: a Pédiatrie Oncology Group study. J. Gin. Oncol. (1993) 11:232-4-2329.
31. ROWINSKY EK, BURKE PJ, KARP JE et al.: Phase I and pharmacodynamic study of Taxol in refractory adult acute leukcmias. Cancer Res. (1989) 49:4640-4647.
32. SAROSY G, KOHN E, STONE DA et al.: Phase I study of Taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J. Gin. Oncol. (1992) 10:1165-1170.
33. WILSON \VH, BERG S, BRYANT G et ah. Paclitaxel ill doxorubicin-refractory or mitomycin-refractory breast cancer: a Phase I/II trial with 96-hour infusion. J. Gin. Oncol. (1994) 12:1021-1629.
34. SPRIGGS DR, TONDINI C: Taxol administered as a 120 hour infusion. Inrest. At'1 Dntgs (1992) 10:275-278.
35. WEISS RB, DONEHOWER RC, WIERNIK PH et al.: Hypcrsensitivity reactions from TaxoL J. Gin. Oncol. (1990) 12:1263-1268.
36. TRUDEAU ME: Docetaxel (Taxotere): an overview of first-line monotherapy. Semin. Oncol. (1995) 22(SuppI. 13):17-21.
37. HOLMES FA. WALTERS KS. THERIAULT KL cl al.: Pliasc II trial of Taxol an active drug in the treatment of metastatic breast cancer. Cancer /;;.
38. VICI P. DI LAUKO S. COXTI L et a!.-. Paclitaxel activity in anthracyclinc refractory breast cancer patients. Ti/wo/iri (1997) 83:661-664.
39. DAVIDSON NG: Single agent paclitaxel as first-line treatment of metastatic breast cancer: the British experience. Semiii. Oncol. (1996) 23(Suppl. 11):6-10.
40. MICHAEL M, BISHOP JF, LEVI JA et al.: Australian multiccntrc Phase II trial of paclitaxel in women with metastatic breast cancer and prior chemotherapy. Mecl.J. Anst. (1997) 166:530-533-
41. SE1DMAN AD. HUDIS C. TIEKSTEN A et al.-. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J. Clin. Oncol. (1995) 13:2575-2581.
42. FOUNTZILAS G, ATHANASSIADES A, GIANNAKAKIS T et ni.: A Phase II study of paclitaxel in advanced breast cancer resistant to anthracyclincs. Eur.J. Gri;/crr(1996) 32A:47-51.
43. GIANNI L, MUNZONE E, CAPRI G et eil.: Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines.J. i\ntl. Cancer Inst. (1995)87:1169-1175.
44. VERMORKEN D, TEN I3OKKEL HUIN1NK WW, MANDJES IAM et al.: High dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: a European Cancer Center trial. Senitn. Oncol. (1995) 22:16-22.
45. SEIDMAN AD, REICHMAN BS, CROWN JP et til.: Paclitaxel as a second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracyclinc response. J. Clin. Oncol. (1995) 15:1152-1159.
46. ABRAMS.IS, VENA DA, BALTZJ etal.: PacUtaxel activity In heavily prctrcatcd breast cancer: a National Cancer Institute Treatment Referral Center trial./ Clin. Oncol. (1995) 13:2056-2065.
47. CONSTENLA M, LORENZO I, GARCIA-ARROYO FR et eil.: Phase II trial of paclitaxel 96-hour infusion with G-CSF in anthracycliiic-rcsistaiit metastatic breast cancer. m1'ivc. Am. Soc. Clin. Oncol. (1997) l6:l65a.
48. BONNETERKE J, TUB1ANA-HULIN M, CHOLLET PH et eil.: Taxol (paclitaxel) 225mg/m2 by 3-hour infusion without G-CSF as first-line therapy in patients with metastatic breast cancer (MBC). Proc. Am. Soc. Clin. Oncol. (1996) 15:179. Abstract.
49. REICHMAN BS, SEIDMAN AD, CROWN JPA et cil.: Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J. Clin. Oncol. (1993) 11:1943-1951.
50. SWAIN S. HINIG S. WALTON L el al.: Phase II trial of paclitaxcl (Taxol) as first-line chemotherapy for metastatic breast cancer (MBC). Pmc. Ain. Soc. Clin. Oncol. (1995) 14:132. Abstract 227.
51. MAMOUNAS E. BROWN A. FISHER B et al.-. 3-Hour high-dose Taxol infusion in advanced hreast cancer: a NSABP Phase II study. I'ntc. Am. Soc. Clin. Oncol. (1995) 14:206. Abstract.
52. LUFTNER D, FLATH li, PRINTZ B cl al.: Weekly fractionated paclitaxcl in metastatic breast cancer-dose optimising study. Eur.j. Ccincer(1997) 33:5196. Abstract 694.
53. BREIER A, LEDBEDINSKY C. PELAYES L et ell.: Phase I/II weekly paclitaxcl 80 mg/m2 in pretreated breast and ovarian cancer. I'roc. Am. Soc. Clin. Oncol. (1997) I6:l63a. Abstract 568.
54. CHANG A. HUI L, BORGS R et cil.: Phase I study of weekly one-hour paclitaxcl treatment in advanced malignant diseases. Pmc. Am. Soc. Clin. One!. (1997) l6:232a. Abstract 817.
55. SEIDMAN AD, HUDIS ÇA. ALBANELJ et cil.: Dose-dense therapy with weekly 1-hour paclitaxcl infusions in the treatment of metastatic breast cancer. J. Clin. Oncol. (1998)16:3353-3361.
56. PEREZ EA, IRWIN DH, PATEL R étal.: A large Phase II trial of paclitaxcl administered as a weekly one hour infusion in patients with metastatic breast cancer. Pmc. Am. Soc. Clin. Oncol. (1999) 18:126a. Abstract.
57. NABHOLTZ J-M, GELMON K, BONTENBAL M et cil.: Multiccnter, randomized comparative study of two doses of paclitaxcl in patients with metastatic breast cancer./ Clin. Oncol. (1996) 14(6):1858-1867.
58. PERETZ T, SULKES A, CHOLLET P et al.: A multicenter, randomized study of two schedules of paclitaxel (PTX) In patients with advanced breast cancer (ABC). Eur. J. awccr(1995) 3KSuppl. 5):S75a.
59. WINER E, BERRY D, DUGGAN D et al.: Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer - results from CALGB 9342. Pmc. Am. Soc. Clin. Oncol. (1998) 17:101a. Abstract 388.
60. MAMOUNAS E, ROWN A, SMITH R et al.: Effect of Taxol duration of infusion in advanced breast cancer (ABC): results from NSABP B-26 trial comparing 3- to 24-hour infusion of high-dose TaxoL Pmc. Am. Suc. Clin. Oncol. (1998) 17:101a. Abstract 389.
61. HOLMES FA, VALERO V, BUZDAR AU et al.: Final results: randomized Phase III trial of paclitaxcl by 3-hr versus 96-hr infusion in patient (pt) with metastatic breast cancer (MBC). Pme. Am. Soc. Clin. Oncol. (1998) 17:1 lOa. Abstract -i26.
62. GAMUCC1 T, PICCARTM, BRUNNING P étal.: Single-agent Taxol (T) versus doxorubicin (D) as first- and second-line chemotherapy (CT) in advanced breast cancer (ABC): final results of an EORTC randomized study with crossover. Pmc. Am. Soc. Clin. Oncol. (1998) 17:llla. Abstract 428.
63. AWADA A. PAKIDAENS R, BKUNING P et ill.: Doxorubicin or Taxol as first-line chemotherapy for mctastatic breast cancer (MBC); Results of an EOKTC-IDBBC/ECSG randomized trial with crossover (EORTC 10923). Breast Cancer Res. Treat. (1997) 46:23. Abstract 2.
64. SLEDGE G \V, NEUBERG D, INGLE.1 el al.: Phase III trial of doxorubicin (A) rs. paclitaxel (T) i'S. doxorubicin + paclitaxel (A + T) as first-line therapy for metastatic breast cancer (MBC): an intcrgroup trial. Am. Soc. Clin. Oncol. (1997) I6:ln. Abstract 2.
65. BISHOP J, DEWAR J, TONER G et al.: Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated mctastatic breast cancer. J. Clin. Oncol. (1999) 17(82355-2364.
66. GIANNI L, MUNZONE E. CAPRI G el al.-. Paclitaxcl by 3-hour infusion in combination with bolus doxorubicine in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-scquence-finding study./ Clin. Oncol. (1995) 13:2688-2699.
67. GEHL J, HOESGAAKD M, PAASKE T et al.: Combined doxorubicin and paclitaxel in advanced breast cancer : effective and cardiotoxic. Ann. Oncol. (1996) 7:687-693.
68. FRASSINETI GL, ZOLI \V, TIENGHI A et al.: Phase I/II study of sequential and combination of paclitaxel and doxorubicin in the treatment of advanced breast cancer. I'mc.Ain. Soc. Clin. Oncol. (1996) 15:103. Abstract.
69. LATORRE A. LORUSSO V, GUIDA M et al.-. Paclitaxel and doxorubicin in the treatment of advanced breast cancer: a Phase I/II study. I'roc. Am. Soc. Clin. Oncol. (1997) I6:179a. Abstract 627.
70. SPARANO .[A, HU P, RAO RM et al: Phase II trial of doxorubicin plus paclitaxel plus G-CSF in mctastatic breast cancer: an Eastern Cooperative Oncology Group trial (E4195). Breast Cancer Res. Treat. (1997) 46:23. Abstract.
71. COLOMER R, MONTERE A, LLUCH A ct al.: circulating Her-2/neu predicts resistance to Taxol/Adriamycin, in mctastatic breast cancer: preliminary results of a multiccntric prospective study, five. Ain. Soc. Clin. Oncol. (1997) I6:140a. Abstract 492.
72. CAZAP E, VENTRIGLIA E, RUBIO G et al.: Taxol plus doxorubicin in the treatment of mctastatic breast cancer. Pmc.Am. Soc. Clin. Oncol. (1996) 15:146. Abstract 248.
73. SLEDGE G\V, ROBERT B, SPARANO JA et a!.: Eastern Cooperative Oncology Group study of paclitaxel and doxorubicin in advanced breast cancer. Semin. Oncol. (1995) 22(Suppl. 6):105-108.
74. SCHXVARTSMANN G, MENKE CH, CALEFFI M et al.: Phase II trial of Taxol, doxorubicin plus G-CSF in patients with mctastatic breast cancer. Proc. A tn.Soc. Clin. Oncol. (1996) 15:126. Abstract 168.
75. HOLMES FA, MADDEN T, NEWMAN RA et al.: Sequence-dependent alteration of doxorubicin pharmacokinctics by paclitaxel in a Phase I study of paclitaxcl and doxorubicin in patients with mctastatic breast cancer./ Clin. Oncol. (1996) 14:2713-2721.
76. FISHERMAN JS, CO\\VAN KH, NOONE M et al:. Phase 1/11 study of 72 hours infusional paclitaxel and doxorubicin with granulocyte colony stimulating factor in patients with mctastatic breast cancer./ Clin. Oncol. (1996) 14:77-1-782.
77. KLEIN JL. DANSEY RD. KARANES C el al:. Induction chemotherapy with doxorubicin and paclitaxcl for mctastatic breast cancer. Breast Cancer Res. Treat. (1997) 46:94. Abstract 405.
78. NORTON L: Evolving concepts in the systemic drug therapy of breast cancer. Semln. Oncol. (1997)24(Suppl. 10):3-10.
79. HENDERSON 1C, BERRY D. DEMETRI G et ah. Improved disease-free (DPS) and overall survival (OS) from the addition of sequential paclitaxcl (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients OPTS) with node-positive primary breast cancer (BC). I'roc. Am. Soc. Clin. Oncol. (1990) 17:390a. Abstract.
80. EXTRA JM, ROUSSEAU F. BRUNO R et al.: Pliase I and pharmacokinctic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res. (1993) 53:1037-1042.
81. BURRIS H, IRVIN R, KÜHN J étal.: Phase I clinical trial of Taxotere administered as either a 2-hour or 6-hour intravenous infusion./ Clin. Oncol. (1993) 11:950-958.
82. BISSETT D, SETANOIANS A, CASSIDYJ et al.-. Phase I and pharmacokinetic study of Taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res. (1993) 53:523-527.
83. l'AZDUR R. NEWMAN RA. NEWMAN BM et al.: Phase I study of Taxotere: five-day schedule. J.Natl. Cancerlnst. (1992) 84:1781-1788.
84. TOMIAK E, PICCART MJ, KERGER J étal: Phase I study of docctaxel administered as a 1-hour intravenous infusion on a weekly basis. / Clin. Oncol. (1994) 12:1458-1467.
85. TAGUCHI T, FURUE H, N1ITANI H et al.: Phase I clinical trial of RP 56976 (docetaxel), a new anticanccr drug. Gau ToKagaku /?jo/jo(1994) 21:1997-2005.
86. VAN OOSTEROM AT, SCHRIVERS D: Docetaxel (Taxotere), a review of preclinical and clinical experience. Part II: clinical experience. Anticancer Drugs (1995) 6:356-368.
87. NABHOLTZ JM: The role of taxanes in the management of breast cancer. Semin. Oncol. (1999) 26(3XSuppl.8):l-3.
88. TRUDEAU ME, EISENHAUER EA, HIGGINS BP et al.: Docetaxel in patients with metastatic breast cancer: a Phase II study of the National Cancer Institute of Canada Clinical Trials Group. / Clin. Oncol. (1996) 14:422-428.
89. DIERAS V, CHEVALLIER B, KERBRAT P et al.: A multiccntrc Phase II study of docetaxel 75 mg/m2 as first-line chemotherapy for patients with advanced breast cancer: a report of the Clinical Screening Group of the EORTC. Br.J. Cancer (\<)9<3) 74:650-656.
90. TEN HOKKEL HUININK \V\V. PROVE AM, PICCAKT M et al.: A Phase II trial with docctaxcl (Taxoterc) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC-ECTG. Ann. Oncol. (1994) 5:527-532.
91. HUDIS CA. SEIDMAN AD, CROWN JPA et ill: Phase II pharmacologie study of docctaxcl as initial chemotherapy for mctastatic breast cancer. .J. Clin. OHCOJ.U996) 14:58-65.
92. CHEVALLIER B, FUMOLEAU P, KERBRAT P et al.: Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a Phase II trial of the Clinical Screening Co-operative Group of the EORTC..J. Clin. Oncol. (1995) 13:314-322.
93. FUMOLEAU P, CHEVALLIER B, KERBRAT P et al.: A niulticcntrc Phase II study of the efficacy and safety of docctaxcl as first-line treatment of advanced breast cancer: a report of the CUnical Screening Group of the EORTC. Ann. Oncol. (1996) 7:165-171.
94. CHAN S. FRIEDRICHS K, NOEL D et ill.: Prospective randomized trial of docetaxcl versus doxorubicin in patients with mctastatic breast cancer. / Clin. Oncol. (1999) 17(8):2341-2354.
95. TEN BOKKEL HUININK \VW, PROVE AM. PICCART M et dl.: A Phase II trial with docctaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer; a study of the EORTC early clinical trials group. Ann. Oncol. (1994) 5:527-532.
96. VAN OOSTEROM AT, DIERAS V, TUBIANA-HULIN M et ill.: Taxoterc in previously treated patients with mctastatic breast carcinoma (MIIC) stratification for anthracycline resistance, five. Am. Soc. Clin. Oncol. (1996) 15:141. Abstract 23.1.
97. ALEXOPOULOS CG, RIGATOS G, EFREMIDOU A et ni: Phase II study of Taxotec monothcrapy in previously treated patients with advanced breast cancer. Etir. J. awcer(1997) 33(Suppl. 8):S153. Abstract 680.
98. VOROBIOF DA, CHASEN MR, MOEKEN R: Phase II trial of single agent docctaxcl in previously treated patients with advanced breast cancer (ABC). /'/DC. Am. Soc. Clin. Oncol. (1996) 15:130. Abstract 185.
99. TERZOLI E, NISTICO C, GARUFI C el ni.: Docetaxcl in advanced breast carcinoma (MBC) patients (pts) pretrcatcd with anthracyclines. Pmc. Am. Soc. Clin. Oncol. (1998) 17:177a. Abstract 682.
100. LEONARD RC, O'BRIEN M, BARRETT-LEE P et al.: A prospective analysis of 390 advanced breast cancer patients treated with Taxotere throughout the UK. Ann. Oncol. (1996) 7(Suppl. 5):19. Abstract 810.
101. SHAPIRO JD, MICHAEL M, MILLWARD MJ et al.: Activity and toxicity of docetaxel (Taxotere) in women with previously treated mctastatic breast cancer. Anst. AZ_J. Meil. (1997) 27:40-44.
102. ADACHI I, WANTABE T, TAKASHIMA S et al.: A late Phase II study of RP 56976 (docctaxel) in patients with advanced or recurrent breast cancer. Br. J. Cancer (1996)73:210-216.
103. TAGUCHI T. HIRATA K. KUNII Y et al.: An early Phase II study of KP 56976 (docetaxel) in patients with breast cancer. Can To Kagakn /?jo/w( 199-4) 21:2-453-2-160.
104. 104i. TAGUCHI T. MORI S, ABE R cl ai: Late Phase II clinical study of RP 56976 (docetaxel) in patients with advanced/recurrent breast cancer. Can Tu Kagakii /?)-o/>o(199i) 21:2625-2632.
105. VALERO V. HOLMES F, WALTERS RS et al.-. Phase II trial of docetaxel: a new, highly effective antineoplastlc agent in the management of patients with anthracycline-resistant mctastatic breast cancer. .J. Clin. Oncol. (1995) 13:2886-2894.
106. KAVDIN P.M. BURRIS HA. COOK G et al.: Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer./ din. Oncol. (1995) 13:2879-2885.
107. BONNETERKE J. GUASTALLA JP, FUMOLEAU P et al.: A Phase II trial of docetaxel in patients with anthracycline resistant metastatic breast cancer. limtst Cancer Kes. Treat. (1995) 37:89. Abstract 305.
108. NABHOLTZ J-M, SENN H.I, BEZWODA WR el ah. Prospective randomized trial of docetaxel versus mitomycin C plus vinblastinc in patients with metastatic breast cancer progressing despite previous anthracyclinc-containing chemotherapy. J. Clin. Oncol. (1999) 17(5M413-1424.
109. SJOSTROM J, MOURIDSEN H, PLUZANSKA A el a!.: Taxotere rersus methotrexate-5-fluorouracil in patients with metastatic breast cancer as 2nd line chemotherapy: a Phase III study. I'mc. Am. Soc. Clin. OHCOJ.U998) 17:llla Abstract.
110. BONNETERRE J, MONNIER A, ROCHE H et al.: Taxotere versus 5-fluorouracil + navelbine in patients with metastatic breast cancer as 2nd line chemotherapy: a Pliase III study. Breast Cancer Kes. Treat. (1997) 50:261. Abstract.
111. DIERAS V: Docetaxel in combination with doxorubicin: a Phase I dose-finding study. Onculogy (1997) 6(Suppl. 6):17-20.
112. NABHOLTZ JM, SMYLIE M, NOEL D et al.: Docctaxel/doxorubicin/ cyclophosphamide in the treatment of metastatic breast cancer. Oncofog)' (1997) IKSuppl. 8):37-il.
113. DIERAS V, BARTHIER S, BEUZEBOC P et al.: Phase II study of docetaxel in combination with doxorubicin as 1st Une chemotherapy of metastatic breast cancer. Breast Cancer Kes. Treat. (1998) 50:262. Abstract.
114. SPARANO JA, JU P, SCHADFER PL et al.: Phase II trial of doxorubicin and docetaxel plus granulocyte-colony stimulating factor in metastatic breast cancer: an Eastern Cooperative Oncology Group trial (E1196). Breast Cancer Kes. Treat. (1998) 50:27. Abstract.
115. NABHOLTZ JM. Docetaxel (Taxotere) plus doxorubicin-bascd combinations: the evidence of activity in breast cancer. Semiii. Oncol. (1999) 26(3KSuppl. 9):7-13.
116. SCHULLER J, CZEJKA M. KLETZL H et al.: Doxorubicin and Taxotere: a pharmacokinetic study of the combination in advanced breast cancer. Five. Am. Sue. Clin. Oncol. (1998) 17:205a. Abstract.
117. I3ELLOT R, ROBERT J. DIERAS V et al.: Taxotere does not change the pharmacokinetic profile of doxorubicine and doxorubicinol. /'me. Am. Soc. Clin. Oncol. (1998) 17:221a. Abstract.
118. HAINSWORTH .ID. HURRIS HA. ERLAND Jü et al.: Phase I trial of docctaxcl administered by weekly infusion in patients with advanced refractory cancer. J. Clin. Oncol. (1998) 16:2KH-2168.
119. LUCK HJ, DONNE S. GLAUHITZ M et al.: Phase I study of weekly docctaxcl in heavily pretrcatcd breast cancer patients. Enr.J. Cancer (.\W1) 33:703a. Abstract.
120. LOFFLER TM, FREUD \V, DROGE C et al.: Activity of weekly Taxotere in patients with mctastatic breast cancer. Pmc. Am. Soc. Clin. Oncol. (1998) 17:113a. Abstract.
121. BURSTEIN HJ, YOUNGER J. BUNNELL CA ct al.: Weekly docctaxel (Taxotere) for metastatic breast cancer: a Phase II trial, five. Am. Soc. Clin. Oncol. (1999) 18:127a. Abstract.
122. LOFFLER TM. Is there a place for 'dose-dense' weekly schedules of the taxoids? Senilii. Oncol. (1998) 25(Suppl. 12):32-3-i.
123. D'INCALCI M, SCHULLER J. COLOMBO T et a!.: Taxoids in combination with anthracyclines and other agents: pharmacokinetic considerations. Sc'iuin. Oncul. (1998) 25(Suppl. 13):16-20.
124. RIVA A, FUMOLEAU P, ROCHE H étal: Efficacy and safety of different corticosteroid prcmcdications in breast cancer patients treated with Taxotere. J'ivc. Am. Suc. Clin. Onl. (1997; l6:188a. Abstract.
125. GIANNI L, VIGANO L. LOCATELLI A et al.: Human pliarmacokinctic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. .J. Clin. Oncol. (1997.) 15:1906-1915.
126. NABHOLTZ JM. FALKSON G, CAMPOS D cl cil.: A Phase III trial comparing doxorubicin (A) and docetaxcl (T) (AT) to doxorubicin and cyclophosphamidc (AC) as first line chemotherapy for MBC. five. Ain. Soc. Clin. Oncol. (1999) 18:127a. Abstract 485.
127. SLAMON D, GODOLPHIN \V, JONES LA el ell.: Studies of the Hcr-2/ncu proto-oncogene in human breast and ovarian cancer. Science 11989) 244:707-712.
128. SLAMON D, LEYLAND-JONES IS, SHAK S et dl.: Addition of herceptin (humanized anti-Hcr2 antibody) to first line chemotherapy for I1EK2 overexprcssing mctastatic breast cancer markedly increases anticancer activity: a randomized, multinational controlled Phase III trial. five. Ain. Soc. Clin. Oncol. (1998) 17:98a. Abstract 377.
129. NORTON L, SLAMON D, LEYLAND-JONES B et eil.: Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anti-IIER2 monoclonal antibody herceptin (H) in HEK2-overexpressing (IIER2+) mctastatic breast cancer (MBC). five. Am. Soc. Clin. Oncol. (1999) 18:127a. Abstract 483.